Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 4c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/29/2026

1. NOW
2. GOOGL
3. MSFT
4. FTNT
5. EBAY
6. TENB
7. BIIB
8. CMG
9. KLAC
10. ETSY

Go back to Xeris Pharmaceuticals Inc. (XERS) Tops Q1 EPS by 4c, Revenues Beat

Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights

May 13, 2021 7:00 AM EDT

Gvoke® quarterly net sales of $8.1 million

Record quarterly Gvoke prescription volume

Strong cash position of $136.0 million

Conference call and webcast today at 8:30 a.m. ET

CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced financial results for the first quarter 2021 and recent highlights.

We are very pleased with our steady, consistently growing financial performance... More